These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Patarroyo ME; Amador R; Clavijo P; Moreno A; Guzman F; Romero P; Tascon R; Franco A; Murillo LA; Ponton G Nature; 1988 Mar; 332(6160):158-61. PubMed ID: 2450281 [TBL] [Abstract][Full Text] [Related]
6. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes. Wang R; Charoenvit Y; Corradin G; De La Vega P; Franke ED; Hoffman SL J Immunol; 1996 Nov; 157(9):4061-7. PubMed ID: 8892640 [TBL] [Abstract][Full Text] [Related]
7. The vaccine is dead--long live the vaccine. Snounou G; Rénia L Trends Parasitol; 2007 Apr; 23(4):129-32. PubMed ID: 17300988 [TBL] [Abstract][Full Text] [Related]
8. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Kaslow DC; Quakyi IA; Syin C; Raum MG; Keister DB; Coligan JE; McCutchan TF; Miller LH Nature; 1988 May; 333(6168):74-6. PubMed ID: 3283563 [TBL] [Abstract][Full Text] [Related]
13. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Bongfen SE; Ntsama PM; Offner S; Smith T; Felger I; Tanner M; Alonso P; Nebie I; Romero JF; Silvie O; Torgler R; Corradin G Vaccine; 2009 Jan; 27(2):328-35. PubMed ID: 18984024 [TBL] [Abstract][Full Text] [Related]
14. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. Etlinger HM; Felix AM; Gillessen D; Heimer EP; Just M; Pink JR; Sinigaglia F; Stürchler D; Takacs B; Trzeciak A J Immunol; 1988 Jan; 140(2):626-33. PubMed ID: 3275719 [TBL] [Abstract][Full Text] [Related]
15. Genetic considerations in the design of a malaria vaccine. Rzepczyk CM P N G Med J; 1989 Dec; 32(4):251-8. PubMed ID: 2483292 [TBL] [Abstract][Full Text] [Related]
16. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604 [TBL] [Abstract][Full Text] [Related]
17. The development of malaria vaccines: SPf66--what next? Tanner M; Alonso PL Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632 [TBL] [Abstract][Full Text] [Related]
18. Construction and evaluation of a multistage combination vaccine against malaria. Zhang Q; Xue X; Qu L; Pan W Vaccine; 2007 Mar; 25(11):2112-9. PubMed ID: 17241708 [TBL] [Abstract][Full Text] [Related]
19. [Malaria: recent immunological acquisitions and therapeutic prospects]. Leri O; Perinelli P; Losi T; Mastropasqua M; Peri C; Tubili S Clin Ter; 1997 Dec; 148(12):655-65. PubMed ID: 9528202 [TBL] [Abstract][Full Text] [Related]